



IBA to Install First Revolutionary *Proteus*[®]*ONE* Solution in Europe

IBA to Make Proton Therapy Available To More Cancer Patients in Nice, France via More Compact and Cost Efficient Therapy Solutions

Louvain-la-Neuve, Belgium, June 29, 2012 - IBA (Ion Beam Applications S.A.), the global high-tech leader in the field of next generation proton therapy and state-of-the-art technologies for treatment and diagnosis of cancer, is pleased to announce that its revolutionary proton therapy solution, *Proteus*[®]*ONE*^{*} will be installed for the first time in Europe. The equipment will be installed at the Centre Antoine-Lacassagne (CAL), in Nice, France. A downpayment of EUR 1.9 million has already been received by IBA and subject to fully approved financing, IBA can expect to receive a total of EUR 20 million for the equipment provided. On top of this, a service contract has also been signed for a period of 10 years.

IBA is a pioneer in proton therapy – this non-invasive and targeted treatment modality brings major advances in cancer therapy for the benefit of patients. Thanks to its ultra-compact size, the *Proteus*[®]*ONE* brings an ideal solution to the constraints linked to the limited space hospitals have to face.

This second-generation proton-beam system includes a [Pencil Beam Scanning](#) dedicated nozzle. Pencil Beam Scanning enables high-definition conformality to cancerous tumors and rapid dose delivery. It also enables clinicians to deploy an emerging proton treatment modality called intensity-modulated proton therapy.

The new equipment is complementary to the medium-energy biomedical cyclotron used at CAL since 1991 to treat eye melanomas. CAL clinicians expect to begin treating with protons in 2015. Initially, CAL's radiation oncologists will use protons to treat ear, nose, throat, base of the skull and pediatric cancers, before expanding their application to other cancers. This first installation and the joint validation of the new system will take place within the framework of a research collaboration between CAL and IBA.

Olivier Legrain, Chief Executive Officer of IBA commented, "We are delighted to install the revolutionary compact solution *Proteus*[®]*ONE* at CAL, thus enabling a greater number of patients to benefit from proton therapy. *Proteus*[®]*ONE* is IBA's innovative solution in response to customer's requirements in terms of cost and space. This project with CAL is the second order of this new system since it was presented in 2011. We look forward to working in close collaboration with CAL's clinicians and medical physicists as they played a key role in helping us design the *Proteus*[®]*ONE* and thanks to whom patients worldwide will be able to benefit from this innovative therapy in the field of oncology."



“This new solution, which meets the cost and space saving requirements, enables patients to benefit from the advantages of proton therapy which are the incomparable accuracy for eradicating cancer cells, whilst preserving surrounding healthy tissue,” said **Professor José Santini, General Director of CAL**. “This will be a major milestone for both our regional cancer center, and nationally for this type of cancer treatment. France will take pride in this new step.”

CAL’s proton therapy center will be the second such facility in France, but the first one with the new compact gantry. The Centre de Protonthérapie of Institut Curie in Orsay (CPO), near Paris, also uses an IBA proton-beam system. It treats about 500 patients a year a majority of which are children with cancer.

About Proton Therapy

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. To date, IBA proton systems are part of more than half of the world’s clinically based proton therapy facilities. They include 12 operational proton therapy centers worldwide, and 10 more centers in development.

**Proteus®ONE is the brand name of a new configuration of the Proteus 235 including some new developments subject to review by competent authorities (FDA, European Notified Bodies, et al.) before marketing. Empath is a registered trademark of IBA Particle Therapy.*

About Centre Antoine-Lacassagne

CAL is one of 20 comprehensive cancer centers in France that make up the UNICANCER Federation. Located in the heart of Nice, near the Centre Hospitalier Universitaire de Nice (Pasteur), CAL provides cancer care to more than 6,000 patients a year, representing 53,000 cancer hospital stays. Website: www.centreantoinelacassagne.org

About IBA

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company’s expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA’s leading fully integrated IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has



installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact

IBA

Jean-Marc Bothy
Chief Financial Officer
Tel: +32 10 47 58 90

For media and investor enquiries:

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
+44 (0) 207 920 2333
IBA@mcomgroup.com